• Cardiome Pharma’s Xydalba treatment for ABSSSI available in UK pharmaceutical-technology
    June 27, 2017
    Canadian pharmaceutical company Cardiome Pharma’s new intravenous (IV) antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, known as Xydalba (dalbavancin hydrochloride), has been made available in the UK.
PharmaSources Customer Service